Observations with Depo-Provera (medroxyprogesterone) in the management of renal tumours.

A total of 30 patients with renal tumours were started on Depo-Provera (medroxyprogesterone) in December 1981 and followed up for 17 to 44 months. The survivors were checked in July 1985. In 2 of the 13 metastasis-free patients deposits of lethal outcome had formed, survival time averaging 27 months. One of the 8 patients with local metastases had died of renal tumour, average survival time being 26 months. Among the 9 patients with distant metastases there are 2 with survival times of 42 and 44 months, respectively. The liver metastases confirmed by ultrasonography in the first, and in the vena cava in the second case at the time of surgery are no longer demonstrable. Survival time in the last-named group averages 14.5 months.